Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ReNeuron to Receive Support from Foundation Fighting Blindness

Published: Wednesday, March 12, 2014
Last Updated: Wednesday, March 12, 2014
Bookmark and Share
Company receive support for its ReN003 retinal stem cell therapy candidate for treatment of retinitis pigmentosa.

ReNeuron Group plc has announced that its ReN003 retinal stem cell therapy candidate for retinitis pigmentosa is to receive support from the US-based Foundation Fighting Blindness (“the Foundation”), the world’s leading private source for inherited retinal disease research funding.

The Foundation has already played a key role in advancing ReNeuron’s ReN003 therapy through its funding of earlier pre-clinical work conducted by the Schepens Eye Research Institute, Massachusetts Eye and Ear (“Schepens”), ReNeuron’s principal US collaborator on the ReN003 programme.

The Foundation is planning to provide additional resources to ReNeuron and its collaborators in support of preparations for initial clinical trials with ReN003, including access to its network of expert pre-clinical and clinical advisers.

The Foundation is also providing further funding towards late pre-clinical work on the ReN003 programme conducted through Schepens.

ReNeuron is using its proprietary human retinal progenitor cells (hRPCs) as the basis of its ReN003 therapeutic candidate targeting retinitis pigmentosa, a group of hereditary diseases of the eye that lead to progressive loss of sight due to cells in the retina becoming damaged and eventually dying.

Pre-clinical studies have demonstrated that, when transplanted into the retina, hRPCs have the potential to rescue existing photoreceptors to help preserve vision, as well as mature into fully functional photoreceptors, allowing for the possibility of restored vision.

ReNeuron’s ReN003 therapy benefits from Orphan Drug Designation in both Europe and the US. The Company and its collaborators are currently completing late pre-clinical development of the ReN003 therapy, ahead of an initial clinical trial application planned for later this year.

Dr. Brian Mansfield, the Foundation’s Deputy Chief Research Officer, said: “ReNeuron is well positioned to advance its stem cell therapy for people with retinitis pigmentosa. We are excited about the prospects this treatment holds for potentially saving and restoring vision in these patients. This progress underscores the Foundation’s unique role in providing early support to advance promising research to the point of industry interest and further investment, while continuing to work with companies like ReNeuron to accelerate the path to the clinic.”

Dr. John Sinden, Chief Scientific Officer of ReNeuron, said: “We are delighted that the Foundation Fighting Blindness will be supporting the development of our ReN003 therapeutic candidate for retinitis pigmentosa. In particular, the Foundation’s extensive knowledge, experience and network of advisers will be invaluable to us as we look to progress the ReN003 programme into its clinical phase.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ReNeuron Announces First Patient Treated in US Phase I/II Clinical Trial
Company has announced that the first patient has been treated with the Company’s cell therapy candidate for the blindness causing disease RP in a first-in-human US clinical trial.
Thursday, March 17, 2016
ReNeuron Receives Notice of Grant of Key US Patent on its Cell Cryopreservation Technology
Company has announced that it has received a notice of allowance for a key patent application covering its cell cryopreservation technology.
Tuesday, February 09, 2016
AGM Trading Update
CTX stem cell therapy candidate currently in a UK Phase II clinical trial.
Friday, September 25, 2015
Preliminary Results for the Year Ended 31 March 2015
Appointment of Olav Hellebø as CEO.
Saturday, July 11, 2015
FDA Grants Fast Track Designation to ReNeuron’s RP Cell Therapy Candidate
Approval to commence a Phase I/II clinical trial in the US with stem cell therapy candidate for RP.
Saturday, May 23, 2015
Long Term Clinical Data from PISCES Stroke Trial
Long term data continue to show good safety profile and evidence of sustained improvements in neurological status and limb function.
Saturday, April 18, 2015
ReNeuron Files Application to Commence Phase I/II Clinical Trial in the US
IND application to commence clinical trial for retinitis pigmentosa with hRPC therapy candidate.
Tuesday, April 14, 2015
ReNeuron AGM Trading Update
Results from the Phase I study with ReN009 announced in the first half of 2015.
Tuesday, September 09, 2014
Further Data from First Clinical Trial of ReNeuron’s Stem Cell Therapy to be Presented at Stroke Conference
Long term data continue to show good safety profile and evidence of sustained reductions in neurological impairment and spasticity.
Friday, May 16, 2014
ReNeuron Receives UK Regulatory Approvals
Company receive approvals to commence Phase II clinical trial in stroke and Phase I clinical trial in critical limb ischaemia.
Friday, March 28, 2014
Scientific News
Drug to Treat Alcohol Use Disorder Shows Promise Among Drinkers With High Stress
The findings suggest that potential future studies with drugs targeting vasopressin blockade should focus on populations of people with AUD who also report high levels of stress.
Scientists Find Lethal Vulnerability in Treatment-Resistant Lung Cancer
The study describes how the drug Selinexor killed lung cancer cells and shrank tumors in mice when used against cancers driven by the aggressive and difficult-to-treat KRAS cancer gene.
Advanced Lymphoma in Remission After T-Cell Therapy
63% of trial participants who recieved two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission.
New Treatment for Immune Cancers
Clinical trial shows new drug holds promise for treating advanced mastocytosis.
Sickle Cell Gene Therapy Passes Test
Researchers found a precision-engineered gene therapy virus reduced sickle-induced red-cell damage in mice with sickle cell disease.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Vitamin C May Boost Leukemia Treatment
Studies show that supplementing an epigenetic cancer drug with vitamin C enhanced the drug's effectiveness.
Inovio Launches Zika Vaccine Trial
Inovio launches Zika vaccine trial in midst of Puerto Rico epidemic to explore early signals of vaccine efficacy.
New Hope for Zika Treatment Found in Large-Scale Screen of Existing Drugs
Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection
FINCH Filgotinib Phase 3 Program Initiated
Galapagos NV reports the initiation of the FINCH global Phase 3 program in rheumatoid arthritis patient populations.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!